In this study, we demonstrate that homoharringtonine (HHT), an FDA-approved therapeutic agent for chronic myeloid leukaemia (CML), inhibits this immune evasion by targeting the FTO/m6A/LILRB4 signalling pathway in monocytic AML. The gene discussed is LILRB4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.